收费全文 | 2354773篇 |
免费 | 195515篇 |
国内免费 | 4106篇 |
医药卫生 | 2554394篇 |
2018年 | 23884篇 |
2016年 | 20313篇 |
2015年 | 23014篇 |
2014年 | 33395篇 |
2013年 | 50685篇 |
2012年 | 68644篇 |
2011年 | 72186篇 |
2010年 | 42341篇 |
2009年 | 40735篇 |
2008年 | 68679篇 |
2007年 | 72998篇 |
2006年 | 73897篇 |
2005年 | 71942篇 |
2004年 | 69255篇 |
2003年 | 66894篇 |
2002年 | 66122篇 |
2001年 | 112300篇 |
2000年 | 116235篇 |
1999年 | 97708篇 |
1998年 | 26183篇 |
1997年 | 23795篇 |
1996年 | 23752篇 |
1995年 | 24466篇 |
1994年 | 23047篇 |
1993年 | 21437篇 |
1992年 | 79278篇 |
1991年 | 76374篇 |
1990年 | 73524篇 |
1989年 | 70786篇 |
1988年 | 65780篇 |
1987年 | 64755篇 |
1986年 | 61294篇 |
1985年 | 58367篇 |
1984年 | 44151篇 |
1983年 | 37544篇 |
1982年 | 22799篇 |
1981年 | 20228篇 |
1980年 | 18934篇 |
1979年 | 41223篇 |
1978年 | 28904篇 |
1977年 | 24228篇 |
1976年 | 22685篇 |
1975年 | 23857篇 |
1974年 | 29538篇 |
1973年 | 27967篇 |
1972年 | 26172篇 |
1971年 | 24114篇 |
1970年 | 22704篇 |
1969年 | 21041篇 |
1968年 | 19096篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献